{
    "persona": "liberal",
    "model": "mixtral:8x7b-instruct-v0.1-q6_K",
    "topic": "healthcare",
    "language": "English",
    "text": "Atogepant shows promising long-term results for migraine prevention, with 70% of patients experiencing a 50% reduction in monthly migraine days at weeks 13-16, maintained over 48 weeks. These encouraging findings offer hope for patients and clinicians alike!",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "4a5f59ee2ac575fe7406bc33864ff711d7687c96da98c557"
}